Close Menu

BMS

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

By exploring a treatment strategy that involves Roche/Plexxikon's investigational pharmacogenomically targeted drug vemurafenib and Bristol-Myers Squibb's newly approved melanoma treatment Yervoy, two large drug developers are hoping to further improve outcomes for a genomically defined patient population.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The study, led by researchers at OHSU, also identified a series of proteins linked to the Src signaling pathway that could prove useful in identifying renal cell carcinoma patients most likely to respond to treatment with Src inhibitors.

The company claims Agilent, 454 Life Sciences, Navigenics, Pfizer, and others are infringing on its patent covering a method for analyzing non-coding DNA sequences.

Bristol-Myers Squibb will now evaluate Tekmira's new lipid nanoparticles for the delivery of siRNA to tumors and tissues outside of the liver.

A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.

The study measured phosphoproteome-wide changes in hematopoietic BaF3 cells in response to perturbation of several Src family kinases, identifying four SFK negative feedback mechanisms that appear to be suppressed in cell lines resistant to the drug.

Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.

The data covers how 3,800 different inhibitors affect 172 kinases. The researchers grouped the proteins based both on sequence and pharmacological relationships and by their interactions with various compound chemotypes.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.